reaffirms fy non-gaap earnings per share view $5.65 to $5.75 including items.
market procedure volumes impacted by covid-19 resurgence.
q2 revenue results reflect unfavorable market impact of covid-19 and health system labor shortages on medical device procedure volumes.
qtrly revenue of $7.8 billion increased 3% reported.
qtrly cardiovascular revenue of $2.827 billion increased 4% as reported and 3% organic.
expect markets to continue to be affected by pandemic in second half of our fiscal year.
excluding impact of ventilator sales declines, qtrly medical surgical revenue increased 6% organic.
qtrly neuroscience revenue of $2.136 billion increased 4% as reported and 3% organic.
